欧洲机构建议预先批准新的约翰逊和约翰逊肺癌治疗。 European agency recommends new Johnson & Johnson lung cancer treatment for advanced approval.

欧洲医药机构委员会建议Johnson & Johnson将Rybrevant(mivantamab)的亚皮型Rybrevant(Rybrevant)用于治疗先进的EGFR变异型非小细胞肺癌患者。 The European Medicines Agency's committee recommended Johnson & Johnson's subcutaneous form of Rybrevant (amivantamab) for patients with advanced EGFR-mutated non-small cell lung cancer. 与静脉注射形式相比,这种配方减少了治疗时间和与注入有关的反应。 This formulation reduces treatment time and infusion-related reactions compared to the intravenous form. 该建议是在第3阶段成功研究结果显示类似有效性之后提出的。 The recommendation follows successful phase 3 study results showing similar effectiveness. 如果获得批准,它可以为患者提供更方便的治疗选择。 If approved, it could offer a more convenient treatment option for patients.